新型冠状病毒肺炎治疗药物的研究进展  

Research progress in drugs for Corona Virus Disease-2019

作　　者：沈俊 严思敏 彭婕[1] SHEN Jun;YAN Simin;PENG Jie(Department of Pharmacy,Drum Tower Hosipital Affiliated to School of Medicine,Nanjing University,Nanjing 210008,China)

机构地区：[1]南京大学医学院附属鼓楼医院药剂科,南京210008

出　　处：《药学服务与研究》2020年第2期145-149,共5页Pharmaceutical Care and Research

摘　　要：本文通过检索并参考目前现有的临床资料与文献报道,阐述新型冠状病毒肺炎(Corona Virus Disease-2019,COVID-19)治疗药物的研究进展,以期为临床治疗提供参考。最新指南推荐的COVID-19治疗药物有α-干扰素、洛匹那韦/利托那韦、利巴韦林联合治疗,另外还可以选择氯喹、阿比多尔以及采用中药辨证论治。已有两例患者分别使用洛匹那韦/利托那韦与瑞德西韦治疗后症状好转,巴瑞替尼理论上可以作为COVID-19的治疗用药。体外实验表明,达芦那韦、阿比多尔、融合肽(EK1)、ABL激酶抑制剂(包括伊马替尼)、替诺福韦+拉夫米定对COVID-19有一定疗效,多种抗病毒药物联合应用可能适用。药物在COVID-19中的疗效和安全性仍需临床试验进一步证实。This article summarizes the research progress in treatment drugs for Corona Virus Disease-2019(COVID-19)by retrieving and referring to the latest clinical data and literature reports,so as to provide reference for clinical treatment.Therapeutic drugs recommended by the latest guidelines were alpha-interferon,lopinavir/ritonavir,and ribavirin combination therapy.In addition,chloroquine,arbidol,as well as bian zheng lun zhi,i.e.diagnosis and treatment based on overall analysis of symptoms and signs,causes,nature and locations of illness and patient physical conditions according to the basic theories of traditional Chinese medicine,can be applied for the treatment of COVID-19.The symptoms of 2 patients treated with lopinavir/ritonavir and redisevir were improved.Theoretically,barretinib could be used as a treatment drug for COVID-19.In vitro experiments have confirmed that darunavir,abidol,fusion peptide(EK1),ABL kinase inhibitors(including imatinib),tenofovir+lavamidine have a certain effect on COVID-19.The combined application of multiple antiviral drugs might be appropriate.The efficacy and safety of the drugs for the treatment of COVID-19 demands further confirmed through clinical trials.

关 键 词：新型冠状病毒肺炎 抗病毒疗法 综述 

分 类 号：R978.7[医药卫生—药品]